These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 24576793

  • 1. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J, Bardenheuer K, Heinemann K.
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J, Möhner S, Heinemann K.
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [Abstract] [Full Text] [Related]

  • 3. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
    Dinger JC, Heinemann LA, Kühl-Habich D.
    Contraception; 2007 May; 75(5):344-54. PubMed ID: 17434015
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
    Dinger J, Do Minh T, Heinemann K.
    Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
    [Abstract] [Full Text] [Related]

  • 6. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
    Dinger J, Bardenheuer K, Heinemann K.
    Climacteric; 2016 Aug; 19(4):349-56. PubMed ID: 27174159
    [Abstract] [Full Text] [Related]

  • 7. Safety of a new oral contraceptive containing drospirenone.
    Heinemann LA, Dinger J.
    Drug Saf; 2004 Aug; 27(13):1001-18. PubMed ID: 15471507
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N, Smith KP.
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A.
    Clin Drug Investig; 2010 May; 30(5):325-36. PubMed ID: 20384388
    [Abstract] [Full Text] [Related]

  • 15. Drospirenone and VTE.
    Leppée M, Eric M, Culig J.
    J Fam Plann Reprod Health Care; 2010 Jan; 36(1):44. PubMed ID: 20067674
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
    Parkin L, Sharples K, Hernandez RK, Jick SS.
    BMJ; 2011 Apr 21; 342():d2139. PubMed ID: 21511804
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.